Recruiting

Testing a new combination treatment for advanced bladder cancer

Plain-English translation of NCT07232602 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Read our Bladder Cancer research guide →

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This study is testing whether a new medication called , when combined with two other cancer drugs (enfortumab vedotin and ), can help treat advanced bladder cancer more effectively. All participants will receive this three-drug combination, given through IV infusions. The goal is to see if this treatment helps people with bladder cancer that has spread or cannot be surgically removed.

Currently, people with advanced bladder cancer have limited treatment options for their first line of therapy. Researchers believe that combining this new medication with two existing cancer treatments might improve outcomes by attacking the cancer in multiple ways at once.

Do you qualify?

You likely qualify if…

you have been diagnosed with bladder cancer that is locally advanced and cannot be removed by surgery, or has spread to other parts of your body
you have not received any prior chemotherapy or systemic therapy for your advanced bladder cancer
you are willing to provide a tissue sample from your tumor (either newly taken or from an archive)
if you have HIV, hepatitis B, or hepatitis C, your infection is well controlled with medication and has an undetectable viral load before the study begins

You likely don't qualify if…

you have severe eye problems, such as dry eye syndrome, corneal disease, or active corneal ulcers
you have active inflammatory bowel disease (such as Crohn's disease or ulcerative colitis) or require immunosuppressive medications for it
you have uncontrolled heart disease, stroke, or significant blood vessel disease within the last 6 months
you have an active autoimmune disease that required treatment in the past 2 years, or a history of stem cell or organ transplant
you have active cancer in your brain or have a history of lung inflammation (pneumonitis) that required steroids

What participation looks like

You would visit a clinic regularly for IV infusions of the three-drug combination over a 3-week cycle. The medication would be given twice per cycle (on Days 1 and 8), with one of the drugs given once per cycle (on Day 1). This treatment would continue for up to about 2 years, unless your cancer progresses or you experience side effects that require stopping. Throughout the study, you would have blood tests and scans to monitor how the treatment is working and to check for any side effects.

AI-generated summary from trial data · Jun 30, 2026 · Not medical advice

Testing a new combination treatment for advanced bladder cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations